Abstract 77P
Background
Neuroblastoma (NBL) is the most common and aggressive cancer in infants, and there are no robust predictive nomograms for NBL. In this study, a database from the Therapeutically Applicable Research to Generate Effective Treatments was applied to develop and validate a prognostic nomogram for the prediction of individual 5-year overall survival (OS) probability in patients with NBL.
Methods
A total of 729 eligible NBL patients with their clinicopathological factors and biological characteristics from the database were assigned to either the training cohort (n = 511) or the validation cohort (n = 218). Independent predictors were identified by fitting the Cox model with lasso penalty and then were assembled into a nomogram to predict survival. The model was developed for predicting individual 5-year OS probability and was then internally and externally validated, calibrated and compared in each cohort.
Results
Four independent prognostic factors (International NBL Staging System stage, ploidy, histology and Children’s Oncology Group risk group) were discriminated and achieved favourable prediction efficacy following the lasso model. The prognostic nomogram incorporated those factors that performed well in the training and validation cohorts with OS (HR = 0.36, 95% CI: 0.27-0.48, P < 0.0 001; HR = 0.54, 95% CI: 0.34-0.86, P = 0.0 086; respectively) and recurrence-free survival (HR = 0.52, 95% CI: 0.40-0.67, P < 0.0 001; HR = 0.66, 95% CI: 0.44-0.99, P = 0.044; respectively).
Conclusions
The robust prognostic nomogram with four independent prognostic factors can accurately and diversely predict OS and recurrence-free survival in NBL patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract